menu
    • menu
    [{"orgOrder":0,"company":"The Progeria Research Foundation","sponsor":"Eiger BioPharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Lonafarnib","moa":"||Ftase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"The Progeria Research Foundation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"The Progeria Research Foundation \/ The Progeria Research Foundation","highestDevelopmentStatusID":"15","companyTruncated":"The Progeria Research Foundation \/ The Progeria Research Foundation"},{"orgOrder":0,"company":"The Progeria Research Foundation","sponsor":"Eiger BioPharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"||Ftase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"The Progeria Research Foundation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"The Progeria Research Foundation \/ The Progeria Research Foundation","highestDevelopmentStatusID":"15","companyTruncated":"The Progeria Research Foundation \/ The Progeria Research Foundation"}]

    Find Clinical Drug Pipeline Developments & Deals by The Progeria Research Foundation

    Menu

    The Progeria Research Foundation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            The Progeria Research Foundation

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            The Progeria Research Foundation

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lonafarnib,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : Eiger BioPharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eiger Receives European Approval for Zokinvy® (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Proce...

                            Details : Zokinvy® (lonafarnib), is a first-in-class disease-modifying agent that blocks the accumulation of defective progerin and progerin-like proteins which leads to cellular instability and premature aging in children and young adults with progeria.

                            Product Name : Zokinvy

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 20, 2022

                            Lead Product(s) : Lonafarnib,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : Eiger BioPharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            The Progeria Research Foundation

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            The Progeria Research Foundation

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lonafarnib,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : Eiger BioPharmaceuticals

                            Deal Size : $95.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million

                            Details : The PRV was granted in conjunction with the recent approval by the U.S. Food and Drug Administration of ZokinvyTM (lonafarnib) for treatment of Progeria and processing-deficient Progeroid Laminopathies.

                            Product Name : Zokinvy

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 23, 2020

                            Lead Product(s) : Lonafarnib,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : Eiger BioPharmaceuticals

                            Deal Size : $95.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth